MAX 40070
Alternative Names: MAX-3; MAX-40070Latest Information Update: 28 Jan 2026
At a glance
- Originator Maxinovel Pharmaceuticals
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alopecia areata; Atopic dermatitis; Psoriasis
Most Recent Events
- 28 Jan 2026 Phase-II clinical trials in Alopecia areata in China (Topical) before January 2026 (Maxinovel pipeline, January 2026)
- 28 Jan 2026 Phase-II clinical trials in Atopic dermatitis in China (Topical) before January 2026 (Maxinovel pipeline, January 2026)
- 28 Jan 2026 Phase-II clinical trials in Psoriasis in China (Topical) before January 2026 (Maxinovel pipeline, January 2026)